作者
F. LI,Zhou Liang,Hao‐Jie Zhong,Xinrong Hu,Zhe Tang,Chen Zhu,Jinhua Shen,Xu Han,Ruoni Lin,Rong Zheng,Rui Tang,Huajing Peng,Xunhua Zheng,Chengqiang Mo,Peisong Chen,Xin Wang,Qiong Wen,Jianbo Li,Xi Xia,Hongjian Ye,Yagui Qiu,Jia-Kuo Yu,Dongying Fu,Jiaqi Liu,Rong Wang,Hai Xie,Yun Guo,Xiaoyan Li,Jinjin Fan,Qinghua Liu,Haiping Mao,Wei Chen,Yi Zhou
摘要
Abstract Group 3 innate lymphoid cells (ILC3s) represent a new population in immune regulation, yet their role in lupus nephritis (LN) remains elusive. In the present work, systemic increases in ILC3s, particularly in the kidney, are observed to correlate strongly with disease severity in both human and murine LN. Using MRL/ lpr lupus mice and a nephrotoxic serum‐induced LN model, this study demonstrates that ILC3s accumulated in the kidney migrate predominantly from the intestine. Furthermore, intestinal ILC3s accelerate LN progression, manifested by exacerbated autoimmunity and kidney injuries. In LN kidneys, ILC3s are located adjacent to B cells within ectopic lymphoid structures (ELS), directly activating B cell differentiation into plasma cells and antibody production in a Delta‐like1 (DLL1)/Notch‐dependent manner. Blocking DLL1 attenuates ILC3s’ effects and protects against LN. Altogether, these findings reveal a novel pathogenic role of ILC3s in B cell activation, renal ELS formation and autoimmune injuries during LN, shedding light on the therapeutic value of targeting ILC3s for LN.